<document id="DDI-MedLine.d83">
    <sentence id="DDI-MedLine.d83.s0" text="Olanzapine: an updated review of its use in the management of schizophrenia.&#10;">
        <entity charOffset="0-9" id="DDI-MedLine.d83.s0.e0" text="Olanzapine" type="drug" />
    </sentence>
    <sentence id="DDI-MedLine.d83.s2" text="Compared with conventional antipsychotics, it has greater affinity for serotonin 5-HT2A than for dopamine D2 receptors. ">
        <entity charOffset="14-40" id="DDI-MedLine.d83.s2.e0" text="conventional antipsychotics" type="group" />
    </sentence>
    <sentence id="DDI-MedLine.d83.s3" text="In large, well controlled trials in patients with schizophrenia or related psychoses, olanzapine 5 to 20 mg/day was significantly superior to haloperidol 5 to 20 mg/day in overall improvements in psychopathology rating scales and in the treatment of depressive and negative symptoms, and was comparable in effects on positive psychotic symptoms. ">
        <entity charOffset="86-95" id="DDI-MedLine.d83.s3.e0" text="olanzapine" type="drug" />
        <entity charOffset="142-152" id="DDI-MedLine.d83.s3.e1" text="haloperidol" type="drug" />
        <pair ddi="false" e1="DDI-MedLine.d83.s3.e0" e2="DDI-MedLine.d83.s3.e1" id="DDI-MedLine.d83.s3.p0" />
    </sentence>
    <sentence id="DDI-MedLine.d83.s4" text="The 1-year risk of relapse (rehospitalisation) was significantly lower with olanzapine than with haloperidol treatment. ">
        <entity charOffset="76-85" id="DDI-MedLine.d83.s4.e0" text="olanzapine" type="drug" />
        <entity charOffset="97-107" id="DDI-MedLine.d83.s4.e1" text="haloperidol" type="drug" />
        <pair ddi="false" e1="DDI-MedLine.d83.s4.e0" e2="DDI-MedLine.d83.s4.e1" id="DDI-MedLine.d83.s4.p0" />
    </sentence>
    <sentence id="DDI-MedLine.d83.s6" text="In contrast, preliminary results from an 8-week controlled study suggested risperidone 2 to 6 mg/day was superior to olanzapine 5 to 20 mg/day against positive and anxiety/depressive symptoms (p &lt; 0.05), although consistent with the first study, both agents demonstrated similar efficacy on measures of overall psychopathology. ">
        <entity charOffset="75-85" id="DDI-MedLine.d83.s6.e0" text="risperidone" type="drug" />
        <entity charOffset="117-126" id="DDI-MedLine.d83.s6.e1" text="olanzapine" type="drug" />
        <pair ddi="false" e1="DDI-MedLine.d83.s6.e0" e2="DDI-MedLine.d83.s6.e1" id="DDI-MedLine.d83.s6.p0" />
    </sentence>
    <sentence id="DDI-MedLine.d83.s8" text="However, preliminary results from an 8-week trial showed comparable cognitive enhancing effects of olanzapine and risperidone treatment in patients with schizophrenia or schizoaffective disorder. ">
        <entity charOffset="99-108" id="DDI-MedLine.d83.s8.e0" text="olanzapine" type="drug" />
        <entity charOffset="114-124" id="DDI-MedLine.d83.s8.e1" text="risperidone" type="drug" />
        <pair ddi="false" e1="DDI-MedLine.d83.s8.e0" e2="DDI-MedLine.d83.s8.e1" id="DDI-MedLine.d83.s8.p0" />
    </sentence>
    <sentence id="DDI-MedLine.d83.s9" text="Several studies indicate that olanzapine has benefits against symptoms of aggression and agitation, while other studies strongly support the effectiveness of olanzapine in the treatment of depressive symptomatology. ">
        <entity charOffset="30-39" id="DDI-MedLine.d83.s9.e0" text="olanzapine" type="drug" />
        <entity charOffset="158-167" id="DDI-MedLine.d83.s9.e1" text="olanzapine" type="drug" />
        <pair ddi="false" e1="DDI-MedLine.d83.s9.e0" e2="DDI-MedLine.d83.s9.e1" id="DDI-MedLine.d83.s9.p0" />
    </sentence>
    <sentence id="DDI-MedLine.d83.s12" text="The most common adverse effects reported with olanzapine are bodyweight gain, somnolence, dizziness, anticholinergic effects (constipation and dry mouth) and transient asymptomatic liver enzyme elevations. ">
        <entity charOffset="46-55" id="DDI-MedLine.d83.s12.e0" text="olanzapine" type="drug" />
    </sentence>
    <sentence id="DDI-MedLine.d83.s14" text="The high acquisition cost of olanzapine is offset by reductions in other treatment costs (inpatient and/or outpatient services) of schizophrenia. ">
        <entity charOffset="29-38" id="DDI-MedLine.d83.s14.e0" text="olanzapine" type="drug" />
    </sentence>
    <sentence id="DDI-MedLine.d83.s15" text="Pharmacoeconomic analyses indicate that olanzapine does not significantly increase, and may even decrease, the overall direct treatment costs of schizophrenia, compared with haloperidol. ">
        <entity charOffset="40-49" id="DDI-MedLine.d83.s15.e0" text="olanzapine" type="drug" />
        <entity charOffset="174-184" id="DDI-MedLine.d83.s15.e1" text="haloperidol" type="drug" />
        <pair ddi="false" e1="DDI-MedLine.d83.s15.e0" e2="DDI-MedLine.d83.s15.e1" id="DDI-MedLine.d83.s15.p0" />
    </sentence>
    <sentence id="DDI-MedLine.d83.s16" text="Compared with risperidone, olanzapine has also been reported to decrease overall treatment costs, despite the several-fold higher daily acquisition cost of the drug. ">
        <entity charOffset="14-24" id="DDI-MedLine.d83.s16.e0" text="risperidone" type="drug" />
        <entity charOffset="27-36" id="DDI-MedLine.d83.s16.e1" text="olanzapine" type="drug" />
        <pair ddi="false" e1="DDI-MedLine.d83.s16.e0" e2="DDI-MedLine.d83.s16.e1" id="DDI-MedLine.d83.s16.p0" />
    </sentence>
    <sentence id="DDI-MedLine.d83.s18" text="CONCLUSIONS: Olanzapine demonstrated superior antipsychotic efficacy compared with haloperidol in the treatment of acute phase schizophrenia, and in the treatment of some patients with first-episode or treatment-resistant schizophrenia. ">
        <entity charOffset="13-22" id="DDI-MedLine.d83.s18.e0" text="Olanzapine" type="drug" />
        <entity charOffset="83-93" id="DDI-MedLine.d83.s18.e1" text="haloperidol" type="drug" />
        <pair ddi="false" e1="DDI-MedLine.d83.s18.e0" e2="DDI-MedLine.d83.s18.e1" id="DDI-MedLine.d83.s18.p0" />
    </sentence>
    </document>